Evidence map›Paper›PMID 41279721›Full record

ArticlebioRxiv : the preprint server for biology2025

Generative Design of Cell Type-Specific RNA Splicing Elements for Programmable Gene Regulation.

Xi Dawn Chen, Maile Jim, Mounica Vallurupalli, Kai Cao, Andrea Navarro Torres, Jing Wesley Leong, Yifan Zhang, David Wollensak, Qiyu Gong, Jing Sun and 8 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Xi Dawn ChenBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID 0000-0001-8127-6014
Maile JimBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID 0009-0004-2972-6582
Mounica VallurupalliBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID 0000-0002-1995-5283
Kai CaoBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Andrea Navarro TorresBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Jing Wesley LeongBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Yifan ZhangBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
David WollensakBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Qiyu GongBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Jing SunBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Mehdi BorjiBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Gail SchorBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Sofia MrowkaBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Margaret HuBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Anisha LaumasBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Jennifer A RothBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Todd GolubBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Fei ChenBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID 0000-0003-2308-3649

Funding

Training Program in Molecular HematologyT32HL116324 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI NANCY BERLINER · 2013 to 2026
$7.4M
Making cancer precision medicine real: bottlenecks and opportunitiesR35CA242457 · NCI · BROAD INSTITUTE, INC. · PI GOLUB, TODD R. · 2019 to 2025
$6.9M
COVID19 Slide-seqR01HG010647 · NHGRI · BROAD INSTITUTE, INC. · PI Fei Chen, Evan Z Macosko · 2019 to 2026
$6.0M
Characterizing glioma heterogeneity with novel multiplexed nanoscale imaging technologiesDP5OD024583 · OD · BROAD INSTITUTE, INC. · PI CHEN, FEI · 2017 to 2021
$2.2M
NCI NIH HHS R35 CA242457NHGRI NIH HHS R01 HG010647NHLBI NIH HHS T32 HL116324NIH HHS DP5 OD024583
6 · The paper itself

Abstract

Programmable control of gene expression in specific cell types is essential for both basic discovery and therapeutic intervention, yet current strategies lack scalability across diverse cellular contexts. Here, we introduce SPICE (Splicing Proportions In Cell types), an integrated experimental and computational framework that harnesses alternative RNA splicing as a programmable modality for cell type-specific gene regulation. To power SPICE, we constructed a massively parallel reporter assay (MPRA) comprising 46,372 human-derived sequences and profiled exon skipping across 43 cell lines spanning 10 lineages, uncovering widespread cell type-specific exon skipping. Using this data, we trained deep learning models that both predict splicing in unseen contexts and generate synthetic sequences with programmed, cell type-specific splicing patterns. Leveraging these models, we further engineered sequences that selectively splice in cells harboring oncogenic splicing factor mutations, demonstrating translational potential. SPICE provides a generalizable strategy for dissecting splicing regulation and engineering alternative splicing as a gene expression regulatory layer for research and therapeutic applications.

Identifiers

PMID41279721
PMCPMC12637576

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.